Powerful Webinar Series Unites Sygnature and Altasciences
Sygnature has joined forces with Altasciences, a CRO/CDMO in the U.S. and Canada specializing in a flexible, innovative approach to comprehensive early stage drug development, to deliver a series of insightful and thought-provoking webinars exploring the challenges of developing novel CNS-active drugs, and the importance of an integrated non-clinical and clinical approach.
The series is free to attend and will take place over 12-18 months, delving into a range of important themes in the development and regulation of CNS-active drugs, including: Abuse Potential, Physical vs Psychological Dependence, Drug Impaired Driving and Cognition, Hallucinogens, Nicotine and Tobacco, and more.
Senior scientists from both companies will take part in each interactive webinar, sharing knowledge gained from decades of experience in the field and providing valuable insight for those working, or interested in working, in the development of CNS-active drugs. Each session will also give participants a chance to pose questions in a Q&A session.
The first webinar, titled: To Control or be Controlled – Navigating the abuse potential evaluation of CNS-active drugs for EU and US submissions, will take place on 11 March at 16:00 GMT (11:00 ET). The webinar will be presented by Dr Andy Mead, Head of Drug Abuse and Substance Use Disorders at Sygnature Discovery, and Dr Beatrice Setnik, Chief Scientific Officer – Scientific & Regulatory Affairs at Altasciences.
Dr Mead said, “Our two companies and their scientists have enjoyed a strong working relationship for many years, sharing a well-aligned ethos and complementary service offerings. The idea for this series grew naturally out of discussions between scientists at both organisations, recognising that combining our experience and insight could provide something of real value to those engaged in this field of research. It’s an exciting chance to share and learn with some of the best in the industry.”
Dr Setnik stated, “The strong working relationship between Sygnature and Altasciences has provided a seamless transition to clients who are engaging in preclinical and clinical abuse potential studies. The collective scientific and regulatory experience across both sites greatly helps our clients when making critical decisions about their drug development plans and in preparing for key regulatory meetings. Our collective aim is to provide the best strategy and direction for our clients, an offering that is made stronger by a great partnership with Sygnature and their renowned scientific team.”
You can keep up to date with upcoming webinars through either company websites:
Updates will also be published on both companies’ social media channels: